Latest Ask the Experts

PET/CT for Prostate Cancer

Novel PET radiotracers have shown great potential in the early diagnosis and staging of PCa, detection of post-treatment recurrence, and monitoring of metastases not previously ...

RP vs Radiation for High-Risk PCa

Physicians who treat patients with high-risk prostate cancer remain uncertain as to the optimal treatment approach, in part due to difficulty in interpreting study data.

New PCa Grading System Embraced

Endorsed by the International Society of Urological Pathology in 2014, the 5-tier Gleason grade group system is used routinely today in pathology reports and physician ...

Overuse of PCa Scans May Be Easing

Efforts by physician groups in recent years to discourage inappropriate use of radiologic imaging for the initial staging of men with newly diagnosed low-risk disease ...

The Role of MRI in Prostate Cancer Management

An interview with Ashutosh K. Tewari, MBBS, MCh

Latest Prostate Cancer News

PET/CT Imaging Phenotype Tied With Survival in mCRPC

PET/CT Imaging Phenotype Tied With Survival in mCRPC

Assessments of androgen receptor, glycolysis prognostic in castration-resistant prostate cancer.

Testosterone Therapy May Lower Prostate Cancer Incidence

Testosterone Therapy May Lower Prostate Cancer Incidence

Hypogonadal men who received testosterone replacement therapy had a lower incidence of prostate cancer than those who did not, and their cancers were less severe.

Second-Line Enzalutamide May Benefit Some mCRPC Patients

Second-Line Enzalutamide May Benefit Some mCRPC Patients

In a prospective study, mCRPC patients placed on enzalutamide after their disease progressed while on abiraterone therapy had a median radiographic progression-free survival of 8.1 months.

Active Surveillance Required After Prostate Cancer Focal Ablation

Active Surveillance Required After Prostate Cancer Focal Ablation

In a small but meaningful number of patients, Gleason pattern 4 disease missed by MRI and systematic biopsy is present outside the focal ablation zone.

Genetic Variant Predicts Faster Time to Prostate Cancer Metastasis

Genetic Variant Predicts Faster Time to Prostate Cancer Metastasis

The variant HSD3B1 allele increases the likelihood of metastasis in men receiving androgen-deprivation therapy for biochemically recurrent disease after radiotherapy for localized PCa.

Men With PCa Most Likely to Die From Other Causes

Men With PCa Most Likely to Die From Other Causes

Non-metastatic prostate cancer patients are more likely to die from causes other than the disease.

Prostate Cancer Hormone Therapy Ups Cardiac Risks

Prostate Cancer Hormone Therapy Ups Cardiac Risks

Exposure to androgen-deprivation therapy was associated with a nearly 2-fold increased risk of heart failure among men without pre-existing cardiovascular disease.

Brachytherapy + EBRT for High-Risk PCa Offers 'Excellent' Outcomes

Brachytherapy + EBRT for High-Risk PCa Offers 'Excellent' Outcomes

Biochemical failure and prostate cancer-specific mortality rates were 13.3% and 4.9% at 10 years, respectively.

Prostate Cancer Pathologic Stage Alone Independently Predicts BCRFS

Prostate Cancer Pathologic Stage Alone Independently Predicts BCRFS

Pathologic stages T3a and T3b versus T2a were associated with 8.45 and 7.1 times increased risk of biochemical recurrence on multivariable analysis.

Testosterone Patterns Predict Prostate Cancer Risk

Testosterone Patterns Predict Prostate Cancer Risk

The later a man's testosterone level dropped below 12.1 nmol/L, the lower his lifetime risk for prostate cancer.

BRCA2 Mutations Tied With Poor Survival, Progression in mCRPC

BRCA2 Mutations Tied With Poor Survival, Progression in mCRPC

Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.

IMRT for Prostate Cancer Radiation Therapy Soars

IMRT for Prostate Cancer Radiation Therapy Soars

Use of intensity-modulated radiation therapy for prostate cancer increased from 3.5% to 64% from 2002 to 2012.

Prostate Cancer Risk Lower in NSAID Users

Prostate Cancer Risk Lower in NSAID Users

In a case-control study, men who had ever used non-steroid anti-inflammatory drugs had a 23% decreased risk of prostate cancer.

Prostate Cancer Active Surveillance Use Low, But Increasing

Prostate Cancer Active Surveillance Use Low, But Increasing

Use of active surveillance for very low-risk prostate cancer rose from 11.6% of patients in 2010 to 27.3% in 2013, study finds.

First Metastasis Site Predicts Prostate Cancer-Specific Survival

First Metastasis Site Predicts Prostate Cancer-Specific Survival

Following curative treatment for localized PCa, 5-year PCa-specific survival rates are higher for patients with initial lymph node or locoregional metastases versus initial metastases in bone only or in multiple sites.

Sign up for free e-Newsletters